¼¼°èÀÇ ¾Öµð½¼º´ Ä¡·áÁ¦ ½ÃÀå
»óǰÄÚµå : 1757940
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 278 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¾Öµð½¼º´ Ä¡·áÁ¦ ½ÃÀåÀº 2030³â±îÁö 9¾ï 4,830¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 6¾ï 8,140¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¾Öµð½¼º´ Ä¡·áÁ¦ ½ÃÀåÀº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 5.7%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 9¾ï 4,830¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ °æ±¸¾àÀº CAGR 6.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 6,140¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñ°æ±¸¾à ºÎ¹®Àº ºÐ¼® ±â°£ Áß CAGR 3.7%ÀÇ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 8,570¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¾Öµð½¼º´ Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 1¾ï 8,570¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 9.1%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â 1¾ï 9,320¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.7%¿Í 5.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¾Öµð½¼º´ Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¾Öµð½¼º´ Ä¡·áÁ¦°¡ ³»ºÐºñÇÐ, Èñ±ÍÁúȯ °ü¸®, È£¸£¸ó ´ëü Çõ½Å ºÐ¾ß¿¡¼­ Àü·«Àû Á߿伺ÀÌ Ä¿Áö°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¾Öµð½¼º´(¿ø¹ß¼º ºÎ½Å ±â´É ºÎÀü)Àº ºÎ½ÅÀÌ ÃæºÐÇÑ ÄÚÆ¼¼Ö°ú ¾Ëµµ½ºÅ×·ÐÀ» »ý»êÇÏÁö ¸øÇÏ´Â °ÍÀÌ Æ¯Â¡ÀÎ Èñ±Í ³»ºÐºñ ÁúȯÀÔ´Ï´Ù. ÀÌ È£¸£¸ó °áÇÌÀº ÇÇ·Î, üÁß °¨¼Ò, ÀúÇ÷¾Ð, »ö¼ÒÄ§Âø µîÀÇ Áõ»óÀ» À¯¹ßÇÕ´Ï´Ù. ÀûÀýÇÑ Ä¡·á¸¦ ¹ÞÁö ¾ÊÀ¸¸é ȯÀڴ ƯÈ÷ ½ºÆ®·¹½º³ª Áúº´À» °ÞÀ» ¶§ »ý¸íÀ» À§ÇùÇÏ´Â ºÎ½Å±â´ÉºÎÀüÁõ¿¡ °É¸± À§ÇèÀÌ ÀÖ½À´Ï´Ù.

¾Öµð½¼º´ÀÌ È¯ÀÚÀÇ »îÀÇ Áú¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú ½É°¢ÇÑ ÇÕº´ÁõÀÇ °¡´É¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ È¿°úÀûÀÎ Ä¡·á Àü·«ÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î Á¶±â ¹ß°ßÀÌ °¡´ÉÇØÁ³°í, ÇöÀç ÁøÇà ÁßÀΠȣ¸£¸ó ´ëü¿ä¹ý¿¡ ´ëÇÑ ¿¬±¸´Â ÀÚ¿¬ÀÇ È£¸£¸ó ¸®µëÀ» ´õ Àß ¸ð¹æÇÏ¿© ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

¼­¹æÇü Á¦Á¦, ÁÖÀÔ ±â¼ú, °³º°È­µÈ Åõ¿© ÇÁ·ÎÅäÄÝÀÌ ¾Öµð½¼º´ °ü¸®¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

±âÁ¸ÀÇ ¾Öµð½¼º´ Ä¡·á´Â Æò»ý¿¡ °ÉÄ£ È£¸£¸ó º¸Ãæ ¿ä¹ýÀÌ ÇÊ¿äÇß½À´Ï´Ù. ÄÚ¸£Æ¼¼ÖÀº º¸Åë ÇÏÀ̵å·ÎÄÚ¸£Æ¼¼Õ, ÇÁ·¹µå´Ï¼Õ, µ¦»ç¸ÞŸ¼Õ°ú °°Àº °æ±¸¿ë ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å·Î º¸ÃæµÇ¸ç, ÇÏ·ç 2-3ȸ Åõ¿©ÇÏ¿© ÀÚ¿¬Àû ÀÏÁֱ⠸®µëÀ» ¸ð¹æÇÕ´Ï´Ù. ¾Ëµµ½ºÅ×·Ð °áÇÌÁõ¿¡´Â Ç÷çµå·ÎÄÚ¸£Æ¼¼Õ ¾Æ¼¼Å×ÀÌÆ®°¡ »ç¿ëµË´Ï´Ù.

»õ·Î¿î Ä¡·á¹ýÀº ÄÚÆ¼¼Ö ºÐºñÀÇ »ý¸®Àû ¸ð¹æÀ» °³¼±ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÇÏ·ç Á¾ÀÏ º¸´Ù ¾ÈÁ¤ÀûÀÎ ÄÚÆ¼¼Ö ¼öÄ¡¸¦ Á¦°øÇϱâ À§ÇØ ¼­¹æÇü ÇÏÀ̵å·ÎÄÚ¸£Æ¼¼Õ Á¦Á¦ ¹× ÈÞ´ë¿ë ÆßÇÁ¸¦ ÀÌ¿ëÇÑ ÇÏÀ̵å·ÎÄÚ¸£Æ¼¼Õ Áö¼ÓÀû ÇÇÇÏÁÖ»ç(CSHI)°¡ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù¹ýÀº Åõ¿© Ƚ¼ö¸¦ ÁÙÀÌ°í ±âÁ¸ Ä¡·á¿¡¼­ ¹ß»ýÇÏ´Â ÇÇÅ©¿Í Æ®·ÎÇÁ¸¦ ÃÖ¼ÒÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

PULSES ¿¬±¸¿Í °°Àº ÀÓ»ó½ÃÇè¿¡¼­ CSHI°¡ ȯÀÚÀÇ Çູ°¨, ¿¡³ÊÁö ¼öÁØ, Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» À¯ÀÇÇÏ°Ô °³¼±ÇÏ´Â °ÍÀ¸·Î ÀÔÁõµÇ¾ú½À´Ï´Ù. ȯÀÚµéÀº ±âÁ¸ °æ±¸ Åõ¿©º¸´Ù ¼ö¾× ¿ä¹ýÀ» ¼±È£Çϸç, ´õ ³ªÀº Áõ»ó Á¶Àý°ú ÇǷΰ¨ °¨¼Ò¸¦ ÀÌÀ¯·Î ²Å¾Ò½À´Ï´Ù.

÷´Ü ¾Öµð½¼º´ Ä¡·áÁ¦ ¼ö¿ä¸¦ ÁÖµµÇϴ ȯÀÚ±º, ÀÓ»óÇöÀå, Áö¿ª ½ÃÀåÀº?

¾Öµð½¼º´Àº ¹Ì±¹¿¡¼­ ¾à 10¸¸ ¸í Áß 1¸íÀÌ ¾Î°í ÀÖ´Â Èñ±ÍÁúȯÀÌÁö¸¸, Á߳⠿©¼ºÀ̳ª ´Ù¸¥ ÀÚ°¡¸é¿ªÁúȯÀ» ¾Î°í Àִ ȯÀÚ µî ƯÁ¤ Áý´ÜÀÌ ¹ßº´Çϱ⠽±½À´Ï´Ù. È¿°úÀûÀÎ °ü¸® Àü·«ÀÇ Çʿ伺Àº ÀÌ·¯ÇÑ Áý´Ü°ú Ä¡·á¸¦ º¹ÀâÇÏ°Ô ¸¸µå´Â µ¿¹Ý ÁúȯÀ» °¡Áø ȯÀÚ¿¡¼­ ƯÈ÷ ½É°¢ÇÕ´Ï´Ù.

ºÏ¹Ì¿Í À¯·´ÀÇ ÀÇ·á ½Ã½ºÅÛÀº źźÇÑ ÀÇ·á ÀÎÇÁ¶ó¿Í º¸Çè »óȯ ÇÁ·¹ÀÓ¿öÅ©¿¡ ÈûÀÔ¾î ÷´Ü Ä¡·á¹ýÀ» äÅÃÇÏ´Â µ¥ ¾ÕÀå¼­°í ÀÖ½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾Æ, ¾ÆÇÁ¸®Ä«, ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¸¹Àº Áö¿ª¿¡¼­´Â Àü¹® Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ¿©ÀüÈ÷ Á¦ÇѵǾî ÀÖÀ¸¸ç, ÀÇ·á °ÝÂ÷¸¦ ÇØ¼ÒÇϱâ À§ÇÑ ¼¼°è º¸°Ç ±¸»óÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

¾Öµð½¼º´ Ä¡·áÁ¦´Â È£¸£¸ó ´ëü¿ä¹ý, ȯÀÚ Áß½É Ä¡·á, Èñ±ÍÁúȯ ¿¬±¸ µî ´Ù¾çÇÑ ¸Æ¶ô¿¡¼­ ¾î¶² Àü·«Àû ¿ªÇÒÀ» ÇÒ ¼ö Àִ°¡?

¾Öµð½¼º´ Ä¡·áÁ¦ÀÇ ¹ßÀüÀº ³»ºÐºñÇÐ ºÐ¾ß¿¡¼­ ¸ÂÃãÇü ÀÇ·á¿Í ȯÀÚ Áß½É Ä¡·á·ÎÀÇ ÀüȯÀ» º¸¿©ÁÖ´Â »ç·ÊÀÔ´Ï´Ù. Ä¡·á ¿ä¹ýÀ» ȯÀÚ °³°³ÀÎÀÇ Çʿ信 ¸Â°Ô Á¶Á¤Çϰí, ÀÚ¿¬ È£¸£¸ó ÆÐÅÏ¿¡ Ãæ½ÇÇÏ°Ô ÀçÇöÇÏ´Â ±â¼úÀ» Ȱ¿ëÇÔÀ¸·Î½á ÀÓ»óÀÇ´Â Ä¡·á °á°ú¸¦ °³¼±Çϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¾Öµð½¼º´¿¡ ´ëÇÑ ¿¬±¸´Â ÀÚ°¡¸é¿ªÁúȯ°ú È£¸£¸ó ´ëü¿ä¹ý¿¡ ´ëÇÑ Æø³ÐÀº ÀÌÇØ¿¡ ±â¿©ÇÕ´Ï´Ù. ÀÌ ÁúȯÀÇ °ü¸®¿¡¼­ ¾òÀº Áö½ÄÀº ´Ù¸¥ ºÎ½Å ±â´É ºÎÀü ¹× ³»ºÐºñ ÁúȯÀÇ Ä¡·á Á¢±Ù¹ý¿¡ ¹Ý¿µµÇ¾î ÀÌ ºÐ¾ß Àü¹ÝÀÇ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

ÇコÄɾ ´õ¿í °³ÀÎÈ­µÇ°í ±â¼úÀûÀ¸·Î ÅëÇÕµÈ ¸ðµ¨·Î °è¼Ó ÁøÈ­ÇÏ´Â °¡¿îµ¥, ¾Öµð½¼º´ °ü¸®ÀÇ Çõ½ÅÀÌ ´Ù¸¥ Èñ±ÍÁúȯ°ú ¸¸¼ºÁúȯÀÇ Ä¡·á¸¦ ¹ßÀü½Ãų ¼ö Àִ û»çÁøÀÌ µÉ ¼ö Àִ°¡?

ºÎ¹®

Ä¡·á(°æ±¸¾à, ºñ°æ±¸¾à); ÃÖÁ¾ »ç¿ë(º´¿ø¡¤Áø·á¼Ò ÃÖÁ¾ »ç¿ë, Áø´Ü ½ÇÇè½Ç ÃÖÁ¾ »ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 47°Ç)

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Addison's Disease Therapeutics Market to Reach US$948.3 Million by 2030

The global market for Addison's Disease Therapeutics estimated at US$681.4 Million in the year 2024, is expected to reach US$948.3 Million by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Oral Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$661.4 Million by the end of the analysis period. Growth in the Parenteral Drugs segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$185.7 Million While China is Forecast to Grow at 9.1% CAGR

The Addison's Disease Therapeutics market in the U.S. is estimated at US$185.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$193.2 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Addison’s Disease Therapeutics Market - Key Trends & Drivers Summarized

Why Are Addison’s Disease Therapeutics Gaining Strategic Importance Across Endocrinology, Rare Disease Management, and Hormone Replacement Innovation?

Addison’s disease, or primary adrenal insufficiency, is a rare endocrine disorder characterized by the adrenal glands' inability to produce sufficient cortisol and, in many cases, aldosterone. This hormonal deficiency can lead to symptoms such as fatigue, weight loss, low blood pressure, and hyperpigmentation. Without appropriate treatment, patients are at risk of life-threatening adrenal crises, especially during periods of stress or illness .

The increasing recognition of Addison’s disease's impact on patient quality of life and the potential for severe complications has underscored the need for effective therapeutic strategies. Advances in diagnostic techniques have improved early detection, while ongoing research into hormone replacement therapies aims to better mimic natural hormonal rhythms, thereby enhancing patient outcomes.

How Are Modified-Release Formulations, Infusion Technologies, and Personalized Dosing Protocols Transforming Addison’s Disease Management?

Traditional treatment for Addison’s disease involves lifelong hormone replacement therapy. Cortisol is typically replaced with oral glucocorticoids such as hydrocortisone, prednisone, or dexamethasone, administered two to three times daily to simulate natural circadian rhythms. Aldosterone deficiency is managed with fludrocortisone acetate .

Emerging therapies focus on improving the physiological mimicry of cortisol secretion. Modified-release hydrocortisone formulations and continuous subcutaneous hydrocortisone infusion (CSHI) via portable pumps have been developed to provide more stable cortisol levels throughout the day. These approaches aim to reduce the frequency of dosing and minimize peaks and troughs associated with conventional therapy .

Clinical trials, such as the PULSES study, have demonstrated that CSHI can significantly improve patient well-being, energy levels, and overall quality of life. Patients reported a preference for infusion therapy over traditional oral dosing, citing better symptom control and reduced fatigue .

Which Patient Populations, Clinical Settings, and Regional Markets Are Driving Demand for Advanced Addison’s Disease Therapeutics?

While Addison’s disease is rare, affecting approximately 1 in 100,000 individuals in the U.S., certain populations are more susceptible, including middle-aged women and individuals with other autoimmune conditions. The need for effective management strategies is particularly acute in these groups, as well as in patients with comorbidities that complicate treatment .

Healthcare systems in North America and Europe are at the forefront of adopting advanced therapies, supported by robust healthcare infrastructure and reimbursement frameworks. In contrast, access to specialized treatments remains limited in many parts of Asia, Africa, and Latin America, highlighting the need for global health initiatives to address disparities in care.

What Strategic Role Will Addison’s Disease Therapeutics Play in the Broader Context of Hormone Replacement Therapy, Patient-Centered Care, and Rare Disease Research?

Advancements in Addison’s disease therapeutics exemplify the shift toward personalized medicine and patient-centered care in endocrinology. By tailoring treatment regimens to individual patient needs and leveraging technologies that closely replicate natural hormone patterns, clinicians can improve outcomes and enhance quality of life for those affected.

Furthermore, research into Addison’s disease contributes to the broader understanding of autoimmune disorders and hormone replacement therapy. Insights gained from managing this condition can inform treatment approaches for other forms of adrenal insufficiency and endocrine disorders, fostering innovation across the field.

As healthcare continues to evolve toward more individualized and technologically integrated models, could the innovations in Addison’s disease management serve as a blueprint for advancing care in other rare and chronic conditions?

SCOPE OF STUDY:

The report analyzes the Addison's Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Oral Drugs, Parenteral Drugs); End-Use (Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â